Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823368 · ClinicalTrials.gov registry record
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
A clinical trial, sponsored by Seaside Therapeutics.
- Completed
- Registry status
NCT00823368: Completed study, sponsored by Seaside Therapeutics.
NCT00823368 is a clinical trial that has completed, run by Seaside Therapeutics. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00823368 has completed, sponsored by Seaside Therapeutics.
- COMPLETED
- Registry status
Study Summary
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.
Interventions
- DRUG STX209
Trial Details
| Field | Value |
|---|---|
| Start Date | 2009-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823368
The ClinicalTrials.gov registry entry for NCT00823368 describes a study currently listed as completed, categorized as an unspecified phase. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STX209 is the first listed.
NCT00823368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823368 about?
NCT00823368 is a clinical study titled "Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001". The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or s...
What is the current status of trial NCT00823368?
This trial is currently completed. The study started on 2009-01.
What interventions are being tested in trial NCT00823368?
The interventions under investigation include: STX209 (DRUG).
Who is sponsoring clinical trial NCT00823368?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.